Abcam, ab181859, Anti-DDAH1 antibody [EPR13921]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal DDAH1 antibody. Suitable for IP, WB, Flow Cyt (Intra), IHC-P and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR13921,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WB, IP, IHC-P, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The DDAH1 protein also known as dimethylarginine dimethylaminohydrolase 1 plays an important role in regulating nitric oxide (NO) production by metabolizing asymmetric dimethylarginine (ADMA) an inhibitor of nitric oxide synthase. This enzyme has a molecular mass of approximately 31 kDa and is widely expressed in various tissues including liver kidney and brain. It impacts the cardiovascular system by controlling ADMA levels which influence endothelial function and vascular tone.
Biological function summary
The actions of DDAH1 contribute significantly to cardiovascular homeostasis. Increased levels of ADMA resulting from impaired DDAH1 activity can lead to decreased NO production impacting cardiovascular health. DDAH1 does not form part of a complex but acts individually to affect NO synthesis through ADMA degradation. Understanding the biological roles of DDAH1 helps to appreciate how NO-mediated processes are tightly regulated within the body and its impact on vascular health.
Pathways
DDAH1 participates actively in the nitric oxide synthesis pathway. It modulates the levels of endothelial nitric oxide synthase (eNOS) by regulating ADMA which serves as an eNOS inhibitor. Through this pathway DDAH1 ensures a balance between NO production and regulation supporting vascular homeostasis and blood pressure control. DDAH1 shares functional connections with proteins like eNOS which are central to maintaining vascular health and preventing endothelial dysfunction.
Dysfunction of DDAH1 links closely to cardiovascular diseases and conditions like atherosclerosis. Elevated ADMA levels resulting from compromised DDAH1 activity contribute to endothelial dysfunction a precursor to atherosclerosis. The interconnected role with eNOS highlights DDAH1's importance in managing ADMA concentrations as imbalances can exacerbate disease progression. Investigating the influence of DDAH1 on these diseases offers insights into potential therapeutic targets for cardiovascular pathologies.